Keytruda

Argus has lifted Merck & Co., Inc. (NYSE: MRK)'s EPS estimates for 2017 from $4.00 to $4.10 due to the company's strong drug pipeline. The analysts elaborated that the pipeline includes an expected increase in sales of Keytruda, a melanoma treatment drug used on President Jimmy Carter, which...

In the past week, Bristol-Myers Squibb Co's (NYSE: BMY) loss has been Merck & Co., Inc.'s (NYSE: MRK) gain. When Bristol-Myers reported back on August 5 that Opdivo did not meet its targets for treatment of advanced non-small cell lung cancer, the stock tanked 16 percent. Merck...

Despite topping the Street view, BMO said the second-quarter results of Merck & Co., Inc. (NYSE: MRK) is not "good enough" to change its Market Perform rating on the stock. Merck's quarterly revenue was about 1 percent above consensus and 1.5 percent above BMO's forecast, while EPS of $0.93 was...

BMO has downgraded Merck & Co., Inc. (NYSE: MRK) shares to Market Perform from Outperform on valuation. "The so called 'TINA' (there is no alternative) effect is not enough for us to remain bullish at these levels; the fundamentals have not improved to justify higher valuations. In fact, we are...

Shares of Merck & Co., Inc. (NYSE: MRK) were trading higher by nearly 2 percent after the company reported positive data from a Phase 3 study evaluating its KEYTRUDA drug in patients with previously untreated advanced non-small cell lung cancer whose tumors expressed high levels of PD-L1....

The new type of drug that uses the body's immune system to fight cancers has hit the bulls eye. But, Reuters has reported that a top U.S. regulator is concerned too many companies are focused on the same approach. This approach disables the PD-1 protein tumors use to dodge the immune system. '...

Goldman Sachs said evidence of Merck & Co., Inc. (NYSE: MRK)'s Keytruda benefit as a single agent continues to build as registrational monotherapy studies read out. Merck's data presented at ASCO (American Society of Clinical Oncology) include updates on new tumors, existing tumors and...

The latest data from TickerTags provides some surprising insight into the major impact former President Jimmy Carter’s melanoma diagnosis and treatment has had on the social media popularity of Merck & Co., Inc. (NYSE: MRK)’s Keytruda. TickerTags monitors social media sites to...

The Dow Jones Industrial Average is off to a rough start in 2015. More than two weeks into the year, it is down 1.75 percent, and half of its 30 components share prices have dropped during that span. However, there have been a few bright spots for the Dow. Here are the five best-performing Dow...